PaceyCuff System Components

PaceyCuff System Essential Components

The importance of components of the current PaceyCuff System are as follows:

a. The  PaceyCuff Urethral Control Device is now the Premier urethral control device available. The recent changes now beginning to be incorporated include a Neoprene Pad system that is closed cell non-absorptive foam with excellent memory and resistance to deformation with prolonged use. This Neoprene will cover the tops and bottoms on the patient contact surfaces. The strap will also be replaced with a ruggedized Neoprene product. The 75 year history of Neoprene in the SCUBA wear garments shows extreme durability. The new compression tab will also appear soon to allow more convenient closure of the device.

b. The PaceyCuff Guard is an essential asset for catching drips and providing daily security as well as night use with absorbables when the PaceyCuff is not in use. 

c. The PaceyCuff Power Sleeve is a device that collects and contains the skin and allows a consistent target for PaceyCuff application which increases continence as it prevents pinching.
The use of a petroleum gel like ,Vaseline, gives great comfort and skin protection when one is using the PaceyCuff System.

d. B3NTH Briefs are a convenient addition to your toolkit that will provide a generous pocket for use of the PaceyCuff Guard.

Prostate Cancer News- Important Therapeutic study on Radiation combined with Hormone Antagonist

Carrie C, Magné N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-mont follow-up of a phase 3, randomised trial [published online October 16, 2019]. Lancet Oncol.  doi: 10.1016/S1470-2045(19)30486-3.

The GETUG-AFU 16 trial enrolled patients from October 19, 2006 to March 30, 2010. Dr Carry and his collaborators randomly assigned 743 men with to receive radiotherapy alone (374 patients) or radiotherapy in addition to goserelin (369 patients). One patient in the radiotherapy alone group later withdrew consent, leaving 373 patients in that group. The median follow-up was 112 months. In the first analysis of the trial, which was published in 2016, only the first progression event was collected, so MFS could not be analyzed, the authors noted.

paceycuff.com